Notícias e Atividades da Everest Medicines

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da Everest Medicines

• Yongqing Luo, Executive Director and Chief Executive Officer
• Wei Fu, Chairman of the Board
• Shidong Jiang, Independent Non-Executive Directors

Criar um alerta
para seguir os movimentos de executivos da Everest Medicines.

Everest Medicines possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Everest Medicines

• Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients – Everest Medicines
• Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients – Everest Medicines
• Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy – Everest Medicines
• Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in “Kidney 360” Magazine – Everest Medicines
• Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy – Everest Medicines
• Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in “Kidney 360” Magazine – Everest Medicines
• Everest Medicines Announces Attendance at the Following September Investor Conferences – Everest Medicines
• Everest Medicines Announces Interim Results for First Half of 2024 – Everest Medicines
• Everest Medicines Announces Interim Results for First Half of 2024 – Everest Medicines
• Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 – Everest Medicines
• View more press releases Close

Redes sociais sobre Everest Medicines

• Everest Medicines na Wikipedia, Google News e Yahoo Finance
• Everest Medicines na LinkedIn, Twitter e YouTube